Yu C.I.BOR-LUEN CHIANG2021-07-022021-07-0220101110-7243https://www.scopus.com/inward/record.uri?eid=2-s2.0-77954551369&doi=10.1155%2f2010%2f548280&partnerID=40&md5=d4838cad9b5bc968038769fca93c9bf9https://scholars.lib.ntu.edu.tw/handle/123456789/567891Chronic hepatitis C virus (HCV) infection remains a serious burden to public health worldwide. Currently, HCV-infected patients could undergo antiviral therapy by giving pegylated IFN- with ribavirin. However, this therapy is only effective in around 50 of patients with HCV genotype 1, which accounts for more than 70 of all HCV infection, and it is not well tolerated for most patients. Moreover, there is no vaccine available. The efforts on identifying protective immunity against HCV have progressed recently. Neutralizing antibodies and robust T cell responses including both CD 4 + and CD 8 + have been shown to be related to the clearance of HCV, which have shed lights on the potential success of HCV vaccines. There are many vaccines developed and tested before entering clinical trials. Here, we would first discuss strategies of viral immune evasion and correlates of protective host immunity and finally review some prospective vaccine approaches against chronic HCV infection. Copyright ? 2010 C. I. Yu and B.-L. Chiang.[SDGs]SDG3alpha interferon; DNA vaccine; gi 5005; hepatitis C vaccine; neutralizing antibody; peginterferon; recombinant protein; ribavirin; unclassified drug; virus vaccine; hepatitis vaccine; CD4 CD8 ratio; clinical trial; disease course; drug development; drug efficacy; drug safety; drug tolerability; genotype; hepatitis C; human; immunization; nonhuman; review; treatment outcome; Hepatitis C virus; immune evasion; immunity; immunology; Hepatitis C virus; Hepacivirus; Hepatitis C, Chronic; Humans; Immune Evasion; Immunity; Viral Hepatitis Vaccinesreview10.1155/2010/548280206254932-s2.0-77954551369